Does it work? Efficacy assessments help to address this simple question, and Buffalo BioLabs offers a range of both in vitro and in vivo efficacy services to assist you in your pursuits. A Project Director, whose qualifications and experience align best with your research interests, will be assigned to provide you with the guidance your looking for in the design & performance of efficacy studies!
In Vivo Efficacy
Our team of competent, PhD level project directors will be with you each step of the way, recommending animal models and study parameters that will allow thorough assessment of your drug candidate.
Tightly adhering to established SOPs and Study Protocols helps to ensure we deliver well-executed studies.
Each team members who works directly with animals is a licensed veterinary technician with research industry experience and AAALAC & IACUC accredited.
Buffalo BioLabs specializes in oncology animal models. Our location adjacent to Roswell Park Cancer Institute, the nations first cancer research hospital, provides us with the opportunity to collaborate with cutting edge clinicians and cancer researchers. Tumor growth and pathology is measured as an indicator of efficacy in oncology models. Survival, physical & behavioral observations, and other animal model endpoints are expertly evaluated in an assortment of commercial or customer provided mouse & rat strains. Combine these models with pathology, immune cell profiling, or other services for a more complete picture!
Syngeneic & Xenograft Tumor Models
Orthotopic and Subcutaneous Transplantation
In Vivo Imaging
Numerous administration routes are available, including:
Learn more about our available oncology models under Research Resources.
Animal Model Development
Our Project Directors can work with you to develop customized animal models for evaluating efficacy. Contact us for additional details.
In Vitro Efficacy
When animals or humans are introduced into research, there are always strong ethical considerations. Exploring in vitro methods of evaluating efficacy eliminates these concerns and can also provide a more direct assessment of efficacy due to the limited and controlled variables. Requiring limited materials and effort, this approach is also the most cost-efficient approach for narrowing down a list of drug candidates.
Used to assess the efficacy against specific bacteria, candidates can be screened against a panel of bacteria or the lowest concentration of a specific compound determined that will prevent bacterial growth, known as the Minimum Inhibitory Concentration (MIC).
Cell Culture Based Anticancer Assays
In vitro cell based assays can be used to screen a panel of compounds for toxicity against target cells, such as a specific type of cancer, for a comparison of on cancer cells vs. normal cells, and to define a concentration range of drug activity. The same design can be employed to understand the effects of radiation on cancer cells. Proliferation, growth inhibition, apoptosis, and custom readouts can be used to characterize drug effects.
Synergistic drug combinations provide greater effects (e.g., cytotoxicity, growth inhibition) than what would be expected from simple addition of the two agents to cells. To determine potential combinations for drug candidates, synergy assays are performed using standard cytotoxicity or clonogenic assays at fixed ratios of drug candidate to conventional agent. Such testing can identify powerful combinations that warrant further investigation (e.g., in vivo). This type of assay can also identify combinations that may be antagonistic (the two agents reduce or negate the activities of each other) and, thus, will not be clinically useful.
Reporter cell lines that contain constructs with target-specific responsive promoters can be used to monitor the effect of drug candidates of specific transcription factors. Typical systems are luciferase-based for rapid, high through put evaluation of candidates either in libraries or as individual candidates using single dose or dose-response assays. Our current panel of specific reporter assays available include p53, NF-κB, and myc. Assay development to meet your specific needs is available.